Related references
Note: Only part of the references are listed.Phase I clinical trial of vaccination with LY6K-derived peptide in patients with advanced gastric cancer
Hajime Ishikawa et al.
GASTRIC CANCER (2014)
HLA-restricted NY-ESO-1 peptide immunotherapy for metastatic castration resistant prostate cancer
Guru Sonpavde et al.
INVESTIGATIONAL NEW DRUGS (2014)
Phase I clinical trial of human vascular endothelial growth factor receptor 1 peptide vaccines for patients with metastatic renal cell carcinoma
K. Yoshimura et al.
BRITISH JOURNAL OF CANCER (2013)
Activation, dysfunction and retention of T cells in vaccine sites after injection of incomplete Freund's adjuvant, with or without peptide
Elise P. Salerno et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
A multi-peptide, dual-adjuvant telomerase vaccine (GX301) is highly immunogenic in patients with prostate and renal cancer
Daniela Fenoglio et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2013)
Therapeutic Destruction of Insulin Receptor Substrates for Cancer Treatment
Hadas Reuveni et al.
CANCER RESEARCH (2013)
Immunotherapeutic benefit of α-interferon (IFNα) in survivin2B-derived peptide vaccination for advanced pancreatic cancer patients
Hidekazu Kameshima et al.
CANCER SCIENCE (2013)
Phase I trial of OTS11101, an anti-angiogenic vaccine targeting vascular endothelial growth factor receptor 1 in solid tumor
Hidetoshi Hayashi et al.
CANCER SCIENCE (2013)
Phase II study of personalized peptide vaccination for refractory bone and soft tissue sarcoma patients
Ryuji Takahashi et al.
CANCER SCIENCE (2013)
Individual Patient-Specific Immunity against High-Grade Glioma after Vaccination with Autologous Tumor Derived Peptides Bound to the 96 KD Chaperone Protein
Courtney A. Crane et al.
CLINICAL CANCER RESEARCH (2013)
Aberrantly glycosylated MUC1 is expressed on the surface of breast cancer cells and a target for antibody-dependent cell-mediated cytotoxicity
Kirstine Lavrsen et al.
GLYCOCONJUGATE JOURNAL (2013)
Mechanism of Action of Conventional and Targeted Anticancer Therapies: Reinstating Immunosurveillance
Laurence Zitvogel et al.
IMMUNITY (2013)
Induction of CD8 T-cell responses restricted to multiple HLA class I alleles in a cancer patient by immunization with a 20-mer NY-ESO-1f (NY-ESO-1 91-110) peptide
Shingo Eikawa et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
Addition of interferon-α to the p53-SLP® vaccine results in increased production of interferon-γ in vaccinated colorectal cancer patients: A phase I/II clinical trial
Eliane C. M. Zeestraten et al.
INTERNATIONAL JOURNAL OF CANCER (2013)
WT1 peptide immunotherapy for gynecologic malignancies resistant to conventional therapies: a phase II trial
Takashi Miyatake et al.
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY (2013)
Selection of Immunostimulant AS15 for Active Immunization With MAGE-A3 Protein: Results of a Randomized Phase II Study of the European Organisation for Research and Treatment of Cancer Melanoma Group in Metastatic Melanoma
Wim H. J. Kruit et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Predictive Gene Signature in MAGE-A3 Antigen-Specific Cancer Immunotherapy
Fernando Ulloa-Montoya et al.
JOURNAL OF CLINICAL ONCOLOGY (2013)
Targeting of Antigens to B Lymphocytes via CD19 as a Means for Tumor Vaccine Development
Yunfeng Ma et al.
JOURNAL OF IMMUNOLOGY (2013)
Multiple therapeutic peptide vaccines consisting of combined novel cancer testis antigens and anti-angiogenic peptides for patients with non-small cell lung cancer
Hiroyuki Suzuki et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2013)
Persistent antigen at vaccination sites induces tumor-specific CD8+ T cell sequestration, dysfunction and deletion
Yared Hailemichael et al.
NATURE MEDICINE (2013)
Azacytidine and erlotinib exert synergistic effects against acute myeloid leukemia
E. Lainey et al.
ONCOGENE (2013)
Synthesized Multiple Antigenic Polypeptide Vaccine Based on B-Cell Epitopes of Human Heparanase Could Elicit a Potent Antimetastatic Effect on Human Hepatocellular Carcinoma In Vivo (Publication with Expression of Concern. See vol. 14, 2019)
Jun Zhang et al.
PLOS ONE (2013)
Breast Cancer Antiestrogen Resistance 3 (BCAR3) Promotes Cell Motility by Regulating Actin Cytoskeletal and Adhesion Remodeling in Invasive Breast Cancer Cells
Ashley L. Wilson et al.
PLOS ONE (2013)
Mucosal Imprinting of Vaccine-Induced CD8+ T Cells Is Crucial to Inhibit the Growth of Mucosal Tumors
Federico Sandoval et al.
SCIENCE TRANSLATIONAL MEDICINE (2013)
Remarkable tumor lysis in a hepatocellular carcinoma patient immediately following glypican-3-derived peptide vaccination An autopsy case
Yu Sawada et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2013)
Trial watch Monoclonal antibodies in cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Immunotherapy of HPV-associated head and neck cancer Critical parameters
Mevyn Nizard et al.
ONCOIMMUNOLOGY (2013)
Universal tumor-reactive helper peptides from telomerase as new tools for anticancer vaccination
Magalie Dosset et al.
ONCOIMMUNOLOGY (2013)
Novel multifunctional antibody approved for the treatment of breast cancer
Domenico Mavilio et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Adoptive cell transfer for anticancer immunotherapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Immunomodulation of the tumor microenvironment by Toll-like receptor-3 (TLR3) ligands
Valerie Chew et al.
ONCOIMMUNOLOGY (2013)
The immunomodulatory effects of bevacizumab on systemic immunity in patients with metastatic melanoma
Aaron S. Mansield et al.
ONCOIMMUNOLOGY (2013)
New immunotherapeutic paradigms for castration-resistant prostate cancer
Lorenzo Galluzzi
ONCOIMMUNOLOGY (2013)
Victories and deceptions in tumor immunology Stimuvax (R)
Guido Kroemer et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Toll-like receptor agonists for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Interferon may be back on track to treat acute myeloid leukemia
Evelien L. J. M. Smits et al.
ONCOIMMUNOLOGY (2013)
Trial watch: DNA vaccines for cancer therapy
Laura Senovilla et al.
ONCOIMMUNOLOGY (2013)
Trial watch Chemotherapy with immunogenic cell death inducers
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Immunostimulatory cytokines
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
TLR3 agonists improve the immunostimulatory potential of cetuximab against EGFR+ head and neck cancer cells
Chwee Ming Lim et al.
ONCOIMMUNOLOGY (2013)
Trial Watch Dendritic cell-based interventions for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Trial watch Oncolytic viruses for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2013)
Trial watch Cardiac glycosides and cancer therapy
Laurie Menger et al.
ONCOIMMUNOLOGY (2013)
Clinical outcome of patients with various advanced cancer types vaccinated with an optimized cryptic human telomerase reverse transcriptase (TERT) peptide: results of an expanded phase II study
A. Kotsakis et al.
ANNALS OF ONCOLOGY (2012)
TOMM34 expression in early invasive breast cancer: a biomarker associated with poor outcome
Mohammed A. Aleskandarany et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Immunological responses in cancer patients after vaccination with the therapeutic telomerase-specific vaccine Vx-001
Eleni-Kyriaki Vetsika et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Survivin-specific T-cell reactivity correlates with tumor response and patient survival: a phase-II peptide vaccination trial in metastatic melanoma
Juergen C. Becker et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
The specific targeting of immune regulation: T-cell responses against Indoleamine 2,3-dioxygenase
Mads Hald Andersen
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
SYT-SSX breakpoint peptide vaccines in patients with synovial sarcoma: A study from the Japanese Musculoskeletal Oncology Group
Satoshi Kawaguchi et al.
CANCER SCIENCE (2012)
Clinical phase I study of elpamotide, a peptide vaccine for vascular endothelial growth factor receptor 2, in patients with advanced solid tumors
Isamu Okamoto et al.
CANCER SCIENCE (2012)
Limited Induction of Tumor Cross-Reactive T Cells without a Measurable Clinical Benefit in Early Melanoma Patients Vaccinated with Human Leukocyte Antigen Class I-Modified Peptides
Paola Filipazzi et al.
CLINICAL CANCER RESEARCH (2012)
Universal Cancer Peptide-Based Therapeutic Vaccine Breaks Tolerance against Telomerase and Eradicates Established Tumor
Magalie Dosset et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Trial of a Glypican-3-Derived Peptide Vaccine for Advanced Hepatocellular Carcinoma: Immunologic Evidence and Potential for Improving Overall Survival
Yu Sawada et al.
CLINICAL CANCER RESEARCH (2012)
Phase I Trial of Overlapping Long Peptides from a Tumor Self-Antigen and Poly-ICLC Shows Rapid Induction of Integrated Immune Response in Ovarian Cancer Patients
Paul Sabbatini et al.
CLINICAL CANCER RESEARCH (2012)
Vaccination using peptides spanning the SYT-SSX tumor-specific translocation
Jordan E. Bloom et al.
EXPERT REVIEW OF VACCINES (2012)
Cancer vaccines: should we be targeting patients with less aggressive disease?
Diane F. Hale et al.
EXPERT REVIEW OF VACCINES (2012)
Multicenter, phase II clinical trial of cancer vaccination for advanced esophageal cancer with three peptides derived from novel cancer-testis antigens
Koji Kono et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
Phase I clinical trial of HER2-specific immunotherapy with concomitant HER2 kinase inhibtion
Erika Hamilton et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2012)
ZNRF3 promotes Wnt receptor turnover in an R-spondin-sensitive manner
Huai-Xiang Hao et al.
NATURE (2012)
Tumour suppressor RNF43 is a stem-cell E3 ligase that induces endocytosis of Wnt receptors
Bon-Kyoung Koo et al.
NATURE (2012)
The secret ally: immunostimulation by anticancer drugs
Lorenzo Galluzzi et al.
NATURE REVIEWS DRUG DISCOVERY (2012)
Louis Pasteur he father of immunology?
Kendall A. Smith
FRONTIERS IN IMMUNOLOGY (2012)
Trial Watch Adoptive cell transfer immunotherapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Combining targeted therapy with immunotherapy (interferon-α) Rational, efficacy in gastrointestinal stromal tumor model and implications in other malignancies
Lei L. Chen et al.
ONCOIMMUNOLOGY (2012)
Dendritic cell inhibition correlates with survival of colorectal cancer patients on bevacizumab treatment
Adriana J. Michielsen et al.
ONCOIMMUNOLOGY (2012)
Can the exome and the immunome converge on the design of efficient cancer vaccines?
Guido Kroemer et al.
ONCOIMMUNOLOGY (2012)
NY-ESO-1 expression in sarcomas A diagnostic marker and immunotherapy target
Jin-Ping Lai et al.
ONCOIMMUNOLOGY (2012)
Trial watch Monoclonal antibodies in cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Trial Watch Immunostimulatory cytokines
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2012)
Trial watch Dendritic cell-based interventions for cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Trial Watch Experimental Toll-like receptor agonists for cancer therapy
Lorenzo Galluzzi et al.
ONCOIMMUNOLOGY (2012)
Widespread CD4+ T-cell reactivity to novel hTERT epitopes following vaccination of cancer patients with a single hTERT peptide GV1001
Else-Marit Inderberg-Suso et al.
ONCOIMMUNOLOGY (2012)
Understanding key assay parameters that affect measurements of trastuzumab-mediated ADCC against Her2 positive breast cancer cells
Timothy Kute et al.
ONCOIMMUNOLOGY (2012)
Trial watch Chemotherapy with immunogenic cell death inducers
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2012)
Trial watch Prognostic and predictive value of the immune infiltrate in cancer
Laura Senovilla et al.
ONCOIMMUNOLOGY (2012)
Trial watch Peptide vaccines in cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2012)
Trial watch FDA-approved Toll-like receptor agonists for cancer therapy
Erika Vacchelli et al.
ONCOIMMUNOLOGY (2012)
Combination immunotherapy using adoptive T-cell transfer and tumor antigen vaccination on the basis of hTERT and survivin after ASCT for myeloma
Aaron P. Rapoport et al.
BLOOD (2011)
Specificity for the tumor-associated self-antigen WT1 drives the development of fully functional memory T cells in the absence of vaccination
Constandina Pospori et al.
BLOOD (2011)
LY6K is a novel molecular target in bladder cancer on basis of integrate genome-wide profiling
R. Matsuda et al.
BRITISH JOURNAL OF CANCER (2011)
Vaccination of patients with cutaneous melanoma with telomerase-specific peptides
Robert E. Hunger et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
hTERT mRNA dendritic cell vaccination: complete response in a pancreatic cancer patient associated with response against several hTERT epitopes
Else M. Inderberg Suso et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2011)
Hypomethylating agents reactivate FOXO3A in acute myeloid leukemia
Sylvain Thepot et al.
CELL CYCLE (2011)
The TLR7/8 ligand resiquimod targets monocyte-derived dendritic cell differentiation via TLR8 and augments functional dendritic cell generation
Holger Hackstein et al.
CELLULAR IMMUNOLOGY (2011)
Toll-Like Receptor 4 Activation in Cancer Progression and Therapy
Alja Oblak et al.
CLINICAL & DEVELOPMENTAL IMMUNOLOGY (2011)
Telomerase Peptide Vaccination Combined with Temozolomide: A Clinical Trial in Stage IV Melanoma Patients
Jon Amund Kyte et al.
CLINICAL CANCER RESEARCH (2011)
Telomerase Peptide Vaccination in NSCLC: A Phase II Trial in Stage III Patients Vaccinated after Chemoradiotherapy and an 8-Year Update on a Phase I/II Trial
Paal Fr. Brunsvig et al.
CLINICAL CANCER RESEARCH (2011)
MAGE-A10 is a nuclear protein frequently expressed in high percentages of tumor cells in lung, skin and urothelial malignancies
Elke Schultz-Thater et al.
INTERNATIONAL JOURNAL OF CANCER (2011)
Immunological and Clinical Effects of Vaccines Targeting p53-Overexpressing Malignancies
R. Vermeij et al.
JOURNAL OF BIOMEDICINE AND BIOTECHNOLOGY (2011)
Vaccination With Patient-Specific Tumor-Derived Antigen in First Remission Improves Disease-Free Survival in Follicular Lymphoma
Stephen J. Schuster et al.
JOURNAL OF CLINICAL ONCOLOGY (2011)
Telomerase-specific GV1001 peptide vaccination fails to induce objective tumor response in patients with cutaneous T cell lymphoma
Christoph Schlapbach et al.
JOURNAL OF DERMATOLOGICAL SCIENCE (2011)
Antibody-Targeted NY-ESO-1 to Mannose Receptor or DEC-205 In Vitro Elicits Dual Human CD8+ and CD4+ T Cell Responses with Broad Antigen Specificity
Takemasa Tsuji et al.
JOURNAL OF IMMUNOLOGY (2011)
Intradermal Vaccinations With RNA Coding for TAA Generate CD8+ and CD4+ Immune Responses and Induce Clinical Benefit in Vaccinated Patients
Susanne M. Rittig et al.
MOLECULAR THERAPY (2011)
Edward Jenner and the small pox vaccine
Kendall A. Smith
FRONTIERS IN IMMUNOLOGY (2011)
Targeting of DEC-205 on human dendritic cells results in efficient MHC class II-restricted antigen presentation
Katrin Birkholz et al.
BLOOD (2010)
A phase II open label trial evaluating safety and efficacy of a telomerase peptide vaccination in patients with advanced hepatocellular carcinoma
Tim F. Greten et al.
BMC CANCER (2010)
Vaccination with autologous dendritic cells pulsed with multiple tumor antigens for treatment of patients with malignant melanoma: results from a phase I/II trial
Redas Trepiakas et al.
CYTOTHERAPY (2010)
Multipolar mitosis of tetraploid cells: inhibition by p53 and dependency on Mos
Ilio Vitale et al.
EMBO JOURNAL (2010)
Topical resiquimod: a promising adjuvant for vaccine development?
Manoli Igartua et al.
EXPERT REVIEW OF VACCINES (2010)
Expression of aberrantly glycosylated Mucin-1 in ovarian cancer
Catharina H. M. J. Van Elssen et al.
HISTOPATHOLOGY (2010)
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer.
Philip W. Kantoff et al.
NEW ENGLAND JOURNAL OF MEDICINE (2010)
Lack of specific γ-retroviral vector long terminal repeat promoter silencing in patients receiving genetically engineered lymphocytes and activation upon lymphocyte restimulation
William R. Burns et al.
BLOOD (2009)
Cancer vaccination with telomerase peptide GV1001
Jon Amund Kyte
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2009)
New perspectives in cancer immunotherapy and immunomonitoring
Viktor Umansky et al.
FUTURE ONCOLOGY (2009)
Generation in vivo of peptide-specific cytotoxic T cells and presence of regulatory T cells during vaccination with hTERT (class I and II) peptide-pulsed DCs
Mark M. Aloysius et al.
JOURNAL OF TRANSLATIONAL MEDICINE (2009)
Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women
J. Paovonen et al.
LANCET (2009)
Immune Responses in Patients with Metastatic Renal Cell Carcinoma Treated with Dendritic Cells Pulsed with Tumor Lysate
A. Soleimani et al.
SCANDINAVIAN JOURNAL OF IMMUNOLOGY (2009)
Carcinomas of an unknown primary site: a curable disease?
A. Levy et al.
ANNALS OF ONCOLOGY (2008)
Targeting p53 to mitochondria for cancer therapy
Lorenzo Galluzzi et al.
CELL CYCLE (2008)
IMP3 predicts aggressive superficial urothelial carcinoma of the bladder
Lioudmila Sitnikova et al.
CLINICAL CANCER RESEARCH (2008)
Phase I immunotherapeutic trial with long peptides spanning the E6 and E7 sequences of high-risk human papillomavirus 16 in end-stage cervical cancer patients shows lowtoxicity and robust immunogenicity
Gemma G. Kenter et al.
CLINICAL CANCER RESEARCH (2008)
Therapeutic vaccines in cancer: moving from immunomonitoring to immunoguiding
Sjoerd H. van der Burg
EXPERT REVIEW OF VACCINES (2008)
Therapeutic dendritic cell vaccination of patients with metastatic renal cell carcinoma - A clinical, phase 1/2 trial
Annika Berntsen et al.
JOURNAL OF IMMUNOTHERAPY (2008)
Immunotherapy of established (pre) malignant disease by synthetic long peptide vaccines
Cornelis J. M. Melief et al.
NATURE REVIEWS CANCER (2008)
Cancer-testis antigen lymphocyte antigen 6 complex locus K is a serologic biomarker and a therapeutic target for lung and esophageal carcinomas
Nobuhisa Ishikawa et al.
CANCER RESEARCH (2007)
Identification of a new hTERT-derived HLA-A*0201 restricted, naturally processed CTL epitope
Mette Thorn et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2007)
The universal character of the tumour-associated antigen survivin
Mads Hald Andersen et al.
CLINICAL CANCER RESEARCH (2007)
Dendritic-cell immunotherapy:: from ex vivo loading to in vivo targeting
Paul J. Tacken et al.
NATURE REVIEWS IMMUNOLOGY (2007)
CPG-7909 (PF-3512676, ProMune®):: toll-like receptor-9 agonist in cancer therapy
Yanal M. Murad et al.
EXPERT OPINION ON BIOLOGICAL THERAPY (2007)
Vaccination of patients with advanced non-small-cell lung cancer with an optimized cryptic human telomerase reverse transcriptase peptide
Irini Bolonaki et al.
JOURNAL OF CLINICAL ONCOLOGY (2007)
Telomerase peptide vaccination of patients with non-resectable pancreatic cancer: a dose escalating phase I/II study
S. L. Bernhardt et al.
BRITISH JOURNAL OF CANCER (2006)
Telomerase peptide vaccination: a phase I/II study in patients with non-small cell lung cancer
Paal F. Brunsvig et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
Cancer regression in patients after transfer of genetically engineered lymphocytes
Richard A. Morgan et al.
SCIENCE (2006)
Inhibition of tumor growth with antiangiogenic cancer vaccine using epitope peptides derived from human vascular endothelial growth factor receptor 1
Hidenobu Ishizaki et al.
CLINICAL CANCER RESEARCH (2006)
Heparanase:: A new metastasis-associated antigen recognized in breast cancer patients by spontaneously induced memory T lymphocytes
Nora Sommerfeldt et al.
CANCER RESEARCH (2006)
Analysis of RNA-binding protein IMP3 to predict metastasis and prognosis of renal-cell carcinoma: a retrospective study
Zhong Jiang et al.
LANCET ONCOLOGY (2006)
Immunologic and clinical responses after vaccinations with peptide-pulsed dendritic cells in metastatic renal cancer patients
Jan Wierecky et al.
CANCER RESEARCH (2006)
Development of a xenogeneic DNA vaccine program for canine malignant melanoma at the Animal Medical Center
PJ Bergman et al.
VACCINE (2006)
Identification of HLA-A2-or HLA-A24-restricted CTL epitopes possibly useful for glypican-3-specific immunotherapy of hepatocellular carcinoma
H Komori et al.
CLINICAL CANCER RESEARCH (2006)
A new dendritic cell vaccine generated with interleukin-3 and interferon-β induces CD8+ T cell responses against NA17-A2 tumor peptide in melanoma patients
M Trakatelli et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2006)
A phase I study of the optimized cryptic peptide TERT572Y in patients with advanced malignancies
D. Mavroudis et al.
ONCOLOGY (2006)
Cancer-testis genes are coordinately expressed and are markers of poor outcome in non-small cell lung cancer
AO Gure et al.
CLINICAL CANCER RESEARCH (2005)
TLR agonists as vaccine adjuvants: comparison of CpG ODN and Resiquimod (R-848)
RD Weeratna et al.
VACCINE (2005)
Revisiting Freund's incomplete adjuvant for vaccines in the developing world
LH Miller et al.
TRENDS IN PARASITOLOGY (2005)
WT1 is a tumor-associated antigen in colon cancer that can be recognized by in vitro stimulated cytotoxic T cells
R Koesters et al.
INTERNATIONAL JOURNAL OF CANCER (2004)
In vivo targeting of antigens to maturing dendritic cells via the DEC-205 receptor improves T cell vaccination
LC Bonifaz et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2004)
Vaccination of cancer patients against telomerase induces functional antitumor CD8+T lymphocytes
RH Vonderheide et al.
CLINICAL CANCER RESEARCH (2004)
Melanoma-associated antigens in esophageal adenocarcinoma:: Identification of novel MAGE-A10 splice variants
J Lin et al.
CLINICAL CANCER RESEARCH (2004)
Mouse homologue of a novel human oncofetal antigen, glypican-3, evokes T-cell-mediated tumor rejection without autoimmune reactions in mice
T Nakatsura et al.
CLINICAL CANCER RESEARCH (2004)
Ring finger protein 43 as a new target for cancer immunotherapy
N Uchida et al.
CLINICAL CANCER RESEARCH (2004)
Long-term specific immune responses induced in humans by a human immunodeficiency virus type 1 lipopeptide-vaccine:: Characterization of CD8+-T-cell epitopes recognized
H Gahéry-Ségard et al.
JOURNAL OF VIROLOGY (2003)
Survivin is a shared tumor-associated antigen expressed in a broad variety of malignancies and recognized by specific cytotoxic T cells
SM Schmidt et al.
BLOOD (2003)
Immunotherapy: past, present and future
TA Waldmann
NATURE MEDICINE (2003)
The danger model: A renewed sense of self
P Matzinger
SCIENCE (2002)
Share Paper
